

ASX RELEASE

10 February 2022

**Change of Director's Interest Notice – Appendix 3Y: Jane Bell**

Appendix 3Y Change of Director's Interest Notice for Mrs. Jane Bell is attached.

This ASX announcement was approved and authorised for release by the Company Secretary of Amplia Therapeutics Limited.

- End -

**For further information:**

Andrew J. Cooke  
Company Secretary  
[andrew@ampliatx.com](mailto:andrew@ampliatx.com)  
[www.ampliatx.com](http://www.ampliatx.com)

**About Amplia Therapeutics Limited**

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

|                       |                                    |
|-----------------------|------------------------------------|
| <b>Name of entity</b> | <b>AMPLIA THERAPEUTICS LIMITED</b> |
| <b>ABN</b>            | <b>16 165 160 841</b>              |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

|                            |                     |
|----------------------------|---------------------|
| <b>Name of Director</b>    | Jane Catherine Bell |
| <b>Date of last notice</b> | 21 November 2021    |

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

|   |   |
|---|---|
| <b>Direct or indirect interest</b>  | Direct  |
| <b>Nature of indirect interest (including registered holder)</b><br><small>Note: Provide details of the circumstances giving rise to the relevant interest.</small> |   |
| <b>Date of change</b>   | 4, 9 & 10 February 2022   |
| <b>No. of securities held prior to change</b>   | J Mrs Jane Catherine Bell<br>346,454 Ordinary Shares<br>23,097 ATXO Listed Options Ex Price \$0.28 Exp 31 Dec 2023<br><br>Mrs Jane Catherine Bell & Mr Geoffrey Bell <Schooner Super Fund A/C><br>1,456,678 Ordinary Shares<br>49,493 ATXO Listed Options Ex Price \$0.28 Exp 31 Dec 2023 |
| <b>Class</b>  | Ordinary Shares   |
| <b>Number acquired</b>  | 222,342   |

+ See chapter 19 for defined terms.

## Appendix 3Y Change of Director's Interest Notice

---

|   |   |
|---|---|
| <b>Number disposed</b>  | Nil   |
| <b>Value/Consideration</b><br>Note: If consideration is non-cash, provide details and estimated valuation   | 4/2/22 - 22,342 shares at \$0.16<br>9/2/22 – 72,864 shares at \$0.17<br>10/2/22 – 127,136 shares at \$0.17  |
| <b>No. of securities held after change</b>  | Mrs Jane Catherine Bell<br>346,454 Ordinary Shares<br>23,097 ATXO Listed Options Ex Price \$0.28 Exp 31 Dec 2023<br><br>Mrs Jane Catherine Bell & Mr Geoffrey Bell <Schooner Super Fund A/C><br>1,679,020 Ordinary Shares<br>49,493 ATXO Listed Options Ex Price \$0.28 Exp 31 Dec 2023 |
| <b>Nature of change</b><br>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | On-market trades  |

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

|  |     |
|--|-----|
| <b>Detail of contract</b>  | Nil |
| <b>Nature of interest</b>  |     |
| <b>Name of registered holder (if issued securities)</b>  |     |
| <b>Date of change</b>  |     |
| <b>No. and class of securities to which interest related prior to change</b><br>Note: Details are only required for a contract in relation to which the interest has changed |     |
| <b>Interest acquired</b>   |     |
| <b>Interest disposed</b>   |     |
| <b>Value/Consideration</b><br>Note: If consideration is non-cash, provide details and an estimated valuation   |     |
| <b>Interest after change</b>   |     |

---

+ See chapter 19 for defined terms.

**Part 3 – <sup>+</sup>Closed period**

|   |    |
|---|----|
| <b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b> | No |
| <b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>  |    |
| <b>If prior written clearance was provided, on what date was this provided?</b>   |    |

10 February 2022

---

+ See chapter 19 for defined terms.